[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100478038":3},{"organization":4,"armGroups":7,"interventions":68,"overallOfficials":98,"centralContacts":103,"locations":109,"responsibleParty":246,"collaborators":248,"id":256,"slug":257,"hasResults":258,"nctId":259,"briefTitle":260,"officialTitle":260,"acronym":261,"eligibilityCriteria":262,"healthyVolunteers":258,"sex":263,"minAge":264,"maxAge":265,"enrollmentInfo":266,"targetDuration":10,"studyType":269,"phases":10,"briefSummary":270,"conditions":271,"keywords":278,"overallStatus":112,"whyStopped":10,"lastUpdateSubmitDate":285,"lastUpdatePostDateStruct":286,"startDateStruct":289,"completionDateStruct":291,"leadSponsor":293,"locationsCount":294},{"fullName":5,"class":6},"Australian & New Zealand Children's Haematology\u002FOncology Group","OTHER",[8,20,24,28,32,36,40,44,48,52,56,60,64],{"label":9,"type":10,"description":11,"interventionNames":12},"High-risk cancers",null,"One of the following two criteria must be met:\n\n1. Confirmed or suspected high-risk malignancy defined as expected overall survival \\\u003C 30% based on current literature for the specific cancer\n2. Cancers for which standard therapy would result in unacceptable and severe morbidity (e.g., infantile fibrosarcoma where definitive surgery would require amputation of limb) Note: This does not include HR neuroblastoma at diagnosis as this group of patients have an overall survival ≥30% and belongs to Cohort 4A.",[13,14,15,16,17,18,19],"Genetic: Whole Genome Sequencing","Genetic: RNA seq","Genetic: DNA Methylation","Genetic: Targeted Panel Sequencing","Genetic: High Throughput Sequencing (in vitro)","Genetic: Patient Derived Xenograft (PDX)(in vivo)","Other: Liquid Biopsy",{"label":21,"type":10,"description":22,"interventionNames":23},"Rare tumors","At least one of the following three criteria must be met:\n\n1. A rare tumor of uncertain prognosis due to rarity of disease\n2. A rare tumor with no established treatment strategy\n3. A cancer where routine histopathological examination has not been able to establish a diagnosis\n4. Confirmed histiocytic disorder AND molecular profiling may facilitate diagnosis and\u002For treatment\n5. Confirmed proliferative vascular or lymphatic malformation AND has failed conventional treatment, e.g., surgery or embolization, OR no appropriate treatment is available AND the disease is organ, limb or life threatening, or debilitating",[13,14,15,16,19],{"label":25,"type":10,"description":26,"interventionNames":27},"Primary central nervous system (CNS) tumours","Patient is suspected or confirmed to have a primary CNS tumor, including low and high-grade tumors",[13,14,15,16,19],{"label":29,"type":10,"description":30,"interventionNames":31},"Neuroblastoma","Patient is suspected or confirmed to have neuroblastoma 4A: HR neuroblastoma at diagnosis 4B: Non-HR neuroblastoma",[13,14,15,16,19],{"label":33,"type":10,"description":34,"interventionNames":35},"Acute myeloid leukemia, myelodysplastic syndrome and other leukemias not classified as ALL","Patient is confirmed by flow cytometry to have acute myeloid leukemia (AML) or other leukemias (Note: Verbal confirmation of flow cytometry result is adequate for enrolment)",[13,14,15,16,19],{"label":37,"type":10,"description":38,"interventionNames":39},"Acute lymphoblastic leukemia (ALL)","Patient is confirmed to have acute lymphoblastic leukemia by flow cytometry (Note: Verbal confirmation of flow cytometry result is adequate for enrolment)",[13,14,15,16,19],{"label":41,"type":10,"description":42,"interventionNames":43},"Lymphomas","Patient is suspected or confirmed to have a lymphoma",[13,14,15,16,19],{"label":45,"type":10,"description":46,"interventionNames":47},"Sarcomas","Patient is suspected or confirmed to have a sarcoma Includes gastrointestinal stromal tumour (GIST), malignant peripheral nerve sheath tumour (MPNST), desmoplastic small round cell tumour (DSRCT)",[13,14,15,16,19],{"label":49,"type":10,"description":50,"interventionNames":51},"Renal tumors","Patient is suspected or confirmed to have a renal tumor Includes clear cell sarcoma of kidney",[13,14,15,16,19],{"label":53,"type":10,"description":54,"interventionNames":55},"Hepatic and biliary tree tumors","Patient is suspected or confirmed to have a liver or biliary tree tumor",[13,14,15,16,19],{"label":57,"type":10,"description":58,"interventionNames":59},"Thyroid and endocrine tumors","Patient is suspected or confirmed to have a thyroid or endocrine cancer",[13,14,15,16,19],{"label":61,"type":10,"description":62,"interventionNames":63},"Other tumors","Patient is suspected or confirmed to have a tumor which does not fit into any of the above",[13,14,15,16,19],{"label":65,"type":10,"description":66,"interventionNames":67},"Germline only","One of the following two criteria must be met:\n\n1. Patients whose submitted tumor sample could not yield sufficient DNA for any molecular analysis AND participants\u002Fparents have consented to return of germline findings.\n2. Patients who do not have appropriate tumor sample to be submitted for molecular profiling may be considered for germline only analysis. Obtaining tumor samples wherever possible will be encouraged.",[13,14,15,16,19],[69,74,78,82,86,90,94],{"type":70,"name":71,"description":72,"armGroupLabels":73,"otherNames":10},"GENETIC","Whole Genome Sequencing","Each tumor sample will be sequenced and analyzed in parallel with its matched normal (germline DNA from the same patient) to enable the identification of somatic aberrations.",[37,33,65,53,9,41,29,61,25,21,49,45,57],{"type":70,"name":75,"description":76,"armGroupLabels":77,"otherNames":10},"RNA seq","Results will be used for bioinformatics analysis for fusion transcripts and gene expression.",[37,33,65,53,9,41,29,61,25,21,49,45,57],{"type":70,"name":79,"description":80,"armGroupLabels":81,"otherNames":10},"DNA Methylation","Genome-wide assessment of DNA methylation will be conducted on all samples where possible.",[37,33,65,53,9,41,29,61,25,21,49,45,57],{"type":70,"name":83,"description":84,"armGroupLabels":85,"otherNames":10},"Targeted Panel Sequencing","Targeted panel sequencing may be performed:\n\n1. When WGS is not feasible or appropriate, e.g., insufficient DNA from fresh or frozen sample or only Formalin-Fixed Paraffin-Embedded (FFPE) material is available\n2. When mosaicism is suspected\n3. When indicated for a disease type",[37,33,65,53,9,41,29,61,25,21,49,45,57],{"type":70,"name":87,"description":88,"armGroupLabels":89,"otherNames":10},"High Throughput Sequencing (in vitro)","High throughput drug screening will be attempted for tumors from Cohort 1 (high-risk cancers with survival \\\u003C30%) and selected tumor types.",[9],{"type":70,"name":91,"description":92,"armGroupLabels":93,"otherNames":10},"Patient Derived Xenograft (PDX)(in vivo)","In vivo drug testing in patient derived xenograft (PDX) will be attempted for tumors from Cohort 1 (high-risk cancers) and selected tumor types.",[9],{"type":6,"name":95,"description":96,"armGroupLabels":97,"otherNames":10},"Liquid Biopsy","Liquid biopsy will be investigated as a non-invasive method for diagnosis of tumors that are difficult to biopsy directly, understanding tumor heterogeneity, monitoring of treatment response, and detection of minimal residual disease (MRD)\u002Frelapse in leukemia, solid and CNS tumors.",[37,33,65,53,9,41,29,61,25,21,49,45,57],[99],{"name":100,"affiliation":101,"role":102},"David Ziegler","SCHN","PRINCIPAL_INVESTIGATOR",[104],{"name":105,"role":106,"phone":107,"phoneExt":10,"email":108},"National Study Coordinator","CONTACT","+61 2 9382 3102","SCHN-ZERO2@health.nsw.gov.au",[110,126,138,150,162,171,183,195,207,216,232],{"facility":111,"status":112,"city":113,"state":10,"zip":10,"country":114,"countryCode":115,"cosmosGeoPoint":116,"geoPoint":121,"contacts":122},"Women's and Children's Hospital","RECRUITING","Adelaide","Australia","AU",{"type":117,"coordinates":118},"Point",[119,120],138.59863,-34.92866,{"lat":120,"lon":119},[123],{"name":124,"role":106,"phone":10,"phoneExt":10,"email":125},"Suzanne Milne","suzanne.milne@sa.gov.au",{"facility":127,"status":112,"city":128,"state":10,"zip":10,"country":114,"countryCode":115,"cosmosGeoPoint":129,"geoPoint":133,"contacts":134},"Queensland Children's Hospital","Brisbane",{"type":117,"coordinates":130},[131,132],153.02809,-27.46794,{"lat":132,"lon":131},[135],{"name":136,"role":106,"phone":10,"phoneExt":10,"email":137},"Natasha Brown","natasha.brown@health.qld.gov.au",{"facility":139,"status":112,"city":140,"state":10,"zip":10,"country":114,"countryCode":115,"cosmosGeoPoint":141,"geoPoint":145,"contacts":146},"Royal Hobart Hospital","Hobart",{"type":117,"coordinates":142},[143,144],147.32941,-42.87936,{"lat":144,"lon":143},[147],{"name":148,"role":106,"phone":10,"phoneExt":10,"email":149},"David Nolan","david.nolan@ths.tas.gov.au",{"facility":151,"status":112,"city":152,"state":10,"zip":10,"country":114,"countryCode":115,"cosmosGeoPoint":153,"geoPoint":157,"contacts":158},"Monash Children's Hospital","Melbourne",{"type":117,"coordinates":154},[155,156],144.96332,-37.814,{"lat":156,"lon":155},[159],{"name":160,"role":106,"phone":10,"phoneExt":10,"email":161},"Amanda St John","Amanda.StJohn@monashhealth.org",{"facility":163,"status":112,"city":152,"state":10,"zip":10,"country":114,"countryCode":115,"cosmosGeoPoint":164,"geoPoint":166,"contacts":167},"Royal Children's Hospital",{"type":117,"coordinates":165},[155,156],{"lat":156,"lon":155},[168],{"name":169,"role":106,"phone":10,"phoneExt":10,"email":170},"Kahlia Fox","clinicaltrialsmanager@rch.org.au",{"facility":172,"status":112,"city":173,"state":10,"zip":10,"country":114,"countryCode":115,"cosmosGeoPoint":174,"geoPoint":178,"contacts":179},"John Hunter Children's Hospital","Newcastle",{"type":117,"coordinates":175},[176,177],151.7801,-32.92953,{"lat":177,"lon":176},[180],{"name":181,"role":106,"phone":10,"phoneExt":10,"email":182},"Rebecca Jensen","Rebecca.Jensen@health.nsw.gov.au",{"facility":184,"status":112,"city":185,"state":10,"zip":10,"country":114,"countryCode":115,"cosmosGeoPoint":186,"geoPoint":190,"contacts":191},"Perth Children's Hospital","Perth",{"type":117,"coordinates":187},[188,189],115.8614,-31.95224,{"lat":189,"lon":188},[192],{"name":193,"role":106,"phone":10,"phoneExt":10,"email":194},"Jennifer McConnell","jennifer.mcconnell@health.wa.gov.au",{"facility":196,"status":112,"city":197,"state":10,"zip":10,"country":114,"countryCode":115,"cosmosGeoPoint":198,"geoPoint":202,"contacts":203},"Sydney Children's Hospital, Randwick","Sydney",{"type":117,"coordinates":199},[200,201],151.20732,-33.86785,{"lat":201,"lon":200},[204],{"name":205,"role":106,"phone":10,"phoneExt":10,"email":206},"Sandra Montez","Sandra.Montez@health.nsw.gov.au",{"facility":208,"status":112,"city":197,"state":10,"zip":10,"country":114,"countryCode":115,"cosmosGeoPoint":209,"geoPoint":211,"contacts":212},"The Children's Hospital at Westmead",{"type":117,"coordinates":210},[200,201],{"lat":201,"lon":200},[213],{"name":214,"role":106,"phone":10,"phoneExt":10,"email":215},"Jun Christian","jun.christian@health.nsw.gov.au",{"facility":217,"status":112,"city":218,"state":219,"zip":220,"country":221,"countryCode":222,"cosmosGeoPoint":223,"geoPoint":227,"contacts":228},"Starship Children's Hospital","Auckland","Grafton","1023","New Zealand","NZ",{"type":117,"coordinates":224},[225,226],174.76349,-36.84853,{"lat":226,"lon":225},[229],{"name":230,"role":106,"phone":10,"phoneExt":10,"email":231},"Sarah Hunter","SHunter@adhb.govt.nz",{"facility":233,"status":234,"city":235,"state":10,"zip":236,"country":221,"countryCode":222,"cosmosGeoPoint":237,"geoPoint":241,"contacts":242},"Christchurch Hospital","NOT_YET_RECRUITING","Christchurch","8011",{"type":117,"coordinates":238},[239,240],172.63333,-43.53333,{"lat":240,"lon":239},[243],{"name":244,"role":106,"phone":10,"phoneExt":10,"email":245},"Kirstie Copeland","Kirstie.copeland@cdhb.health.nz",{"type":247,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[249,252,254],{"name":250,"class":251},"Children's Cancer Institute (CCI)","UNKNOWN",{"name":253,"class":251},"Minderoo Foundation",{"name":255,"class":6},"Medical Research Future Fund","100478038","precision-medicine-for-every-child-with-cancer-100478038",false,"NCT05504772","Precision Medicine for Every Child With Cancer","ZERO2","Inclusion Criteria:\n\n1. Age \\\u003C 18 years Note: Individual patients aged 19 - 25 years old with a pediatric cancer, e.g., neuroblastoma, may be enrolled after discussion with, and at the discretion of, the Study Chair or their delegate.\n2. Life expectancy \\>6 weeks at time of enrolment\n3. Consent i. Signed and dated informed consent for study enrolment from participant aged ≥ 18 years or from parent\u002Fguardian of participant aged \\\u003C18 years. ii. Separate signed and dated informed consent for understanding the role of germline testing and choice for the return of germline results.","ALL","0 Years","25 Years",{"count":267,"type":268},3500,"ESTIMATED","OBSERVATIONAL","To improve outcomes for childhood cancer patients through the implementation of precision medicine.",[272,273,274,275,276,277],"Childhood Cancer","Childhood Solid Tumor","Childhood Brain Tumor","Childhood Leukemia","Refractory Cancer","Relapsed Cancer",[279,280,281,282,283,284],"children","precision medicine","personalised medicine","molecular profiling","pediatric","paediatric","2024-07-16",{"date":287,"type":288},"2024-07-17","ACTUAL",{"date":290,"type":288},"2022-12-16",{"date":292,"type":268},"2030-07",{"name":5,"class":6},11]